Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics

Genentech makes deal with Earendil Labs for cancer bispecifics worth over $1.5 billion.

Genentech has made a deal with Earendil Labs for cancer bispecifics worth over $1.5 billion.

Earendil Labs is an AI heavyweight, but specific details about the agreement's terms or the technology being used are not provided.

The deal comes as Genentech's parent company, Roche, has also made a significant agreement with Atavistik Bio for up to $2 billion.